[
    {
        "id": "osp-2512",
        "type": "article-journal",
        "title": "Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar",
        "author": [
            {
                "family": "Ahmed",
                "given": "Mazen A. Sid"
            },
            {
                "family": "Ibrahim",
                "given": "Emad Bashir"
            },
            {
                "family": "Hamid",
                "given": "Jemal M."
            },
            {
                "family": "Daghfal",
                "given": "Joanne"
            },
            {
                "family": "Alyazidi",
                "given": "Mohammed A."
            },
            {
                "family": "Abdelwahab",
                "given": "Aimen H."
            },
            {
                "family": "Al-Maslamani",
                "given": "Muna A."
            },
            {
                "family": "Al Khal",
                "given": "Abdul Latif"
            },
            {
                "family": "Hadi",
                "given": "Hamad Abdel"
            }
        ],
        "URL": "https://omanscience.com/en/articles/evaluation-of-in-vitro-activity-of-ceftazidime-avibactam-and-ceftolozane-tazobactam-against-esbl-producing-enterobacterales-isolated-from-intensive-care-units-from-qatar",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2022
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2022.89",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "Objectives: Extended-spectrum β-lactamases (ESBLs) mechanism of resistance in Enterobacterales leads to poor clinical outcomes. Ceftazidime/avibactam and ceftolozane/tazobactam are two broad-spectrum antimicrobial combinations that are effective against multidrug-resistant organisms with regional variations. This study aims to evaluate the antimicrobial susceptibility test (AST) for both combinations against ESBL-producing Enterobacterales isolated from intensive care units (ICUs) in tertiary hospitals from November 2012 to October 2013 in Qatar. Methods: A total of 629 Enterobacterales isolates from ICUs were screened for ESBL production using BD-Phoenix confirmed by double-disk potentiation, while ESBL-genes were detected by polymerase chain reaction. The ASTs for ceftazidime/avibactam and ceftolozane/tazobactam were assessed by minimum inhibitory concentration (MIC) test strips. A single isolate that was resistant to both combinations was subjected to whole-genome sequencing. Results: The prevalence of ESBL-producing Enterobacterales isolated from ICUs was 17.3% (109/629) with predominance of Klebsiella pneumoniae (56/109; 51.4%) and Escherichia coli (38/109; 34.9%). The susceptibility of ceftazidime/avibactam and ceftolozane/tazobactam against ESBL-producers was 99.1% (108/109) and most (81/109; 74.3%) had MICs < 0.5 for both combinations. The predominant ESBL-gene was blaCTX-M (72/109; 66.1%). A single isolate that was resistant to both combinations harbored multiple ESBL resistant-genes including blaVEB-5 and blaVIM-2. Conclusions: ESBL-producing Enterobacterales isolated from ICUs were predominantly K. pneumoniae and E. coli, mainly harboring blaCTX-M gene. They were highly susceptible to ceftazidime/avibactam and ceftolozane/tazobactam suggesting potential alternatives to currently available therapeutic options."
    }
]